Literature DB >> 22706171

Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancer.

Virginie Marchand1, Antoine Angelergues, Vanessa Gobaux, David Hajage, Youlia M Kirova, François Campana, Rémi Dendale, Fabien Reyal, Jean-Yves Pierga, Alain Fourquet, Marc A Bollet.   

Abstract

PURPOSE: The lack of pathologic breast cancer response to neoadjuvant chemotherapy (NCT), a negative prognostic factor, has prompted the addition of chemotherapy to adjuvant radiotherapy. This study aims to investigate prospectively the toxicities of adjuvant concurrent chemoradiotherapy versus radiotherapy alone. PATIENTS AND METHODS: Two groups of patients treated for breast cancer between 1997 and 2002 by NCT, surgery, and radiotherapy with or without concurrent chemotherapy, were matched on age, body mass index (BMI), treatment period, treated side, and surgery type. Late toxicity was prospectively evaluated according to the CTCAE v3.0. Acute toxicity was derived from the medical charts.
RESULTS: A total of 52 patients were matched. Median follow-up was 10 years. Acute toxicity was higher in the chemoradiotherapy group compared with the radiotherapy alone group: 37% patients versus 10% experienced a grade 2/3 epithelitis (P=0.002); 48% versus 8% experienced a grade ≥1 mucositis (P=0.00001). Late toxicity was not significantly different in both univariate (51% vs. 49%; P=0.79) and multivariate analyses adjusted on the BMI (P=0.08). In univariate analysis, only the BMI tended to be predictive of toxicity (P=0.07).
CONCLUSIONS: Concurrent chemoradiotherapy after NCT and surgery was associated with increased acute toxicity but not long-term toxicity. The efficacy of this therapeutic strategy should be evaluated to better define its indications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22706171     DOI: 10.1097/COC.0b013e31825466a6

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  2 in total

1.  Helical tomotherapy for inoperable breast cancer: a new promising tool.

Authors:  Ciprian Chira; Youlia M Kirova; Xavier Liem; François Campana; Dominique Peurien; Malika Amessis; Nathalie Fournier-Bidoz; Jean-Yves Pierga; Rémi Dendale; Pierre Bey; Alain Fourquet
Journal:  Biomed Res Int       Date:  2013-09-02       Impact factor: 3.411

2.  Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study.

Authors:  Li-Min Sun; Cheng-Li Lin; Ming-Chia Lin; Ji-An Liang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.